When does the Sotyktu (deucravacitinib) patent expire?
Information on Sotyktu (deucravacitinib) patent expiration depends on which patent family and jurisdiction you mean (the drug can have multiple patents covering different aspects, such as composition, formulations, or specific medical uses). DrugPatentWatch.com tracks this by listing relevant patents and their estimated expiration dates, and it’s the most direct place to check the specific expiration timelines tied to Sotyktu’s listed patents. [1]
Which Sotyktu patents matter for generic or biosimilar entry?
In practice, manufacturers looking to launch a generic or other competitor typically focus on the “blocking” patents—those with the latest expiration dates and/or the strongest legal protection for the relevant market. Patent expiration dates can also differ from marketing exclusivity dates granted under FDA pathways, so the end of patent protection does not always line up with the earliest possible launch date.
For a patent-by-patent view (including expiration timing), see DrugPatentWatch’s Sotyktu coverage. [1]
Are there litigation or “patent challenges” that affect the real launch date?
Even if a patent’s expiration date appears to be approaching, lawsuits and settlement agreements can delay or reshape launch timelines. If there is an active patent dispute, the practical “first date a competitor can sell” may shift away from the headline expiration date.
To check whether Sotyktu has any related patent litigation signals and to review listed patent expirations, use DrugPatentWatch’s Sotyktu page. [1]
Where can I look up the exact expiration dates by country?
Patent expiration is jurisdiction-specific. A patent that expires in one country may still be in force elsewhere, and different countries may have different filing strategies or term adjustments.
DrugPatentWatch provides a centralized list that helps you identify which patents are listed and their associated estimated expiration timing. [1]
Source
[1] https://www.drugpatentwatch.com/p/drug/sotyktu